Free Trial
Dennis Ding

Dennis Ding Analyst Performance

Vice President, Equity Research Analyst at Jefferies Financial Group

Dennis Ding is a stock analyst at Jefferies Financial Group focused in the medical sector, covering 9 publicly traded companies. Over the past year, Dennis Ding has issued 13 stock ratings, including buy and hold recommendations. While full access to Dennis Ding's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Dennis Ding's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
14 Last 1 Years
Buy Recommendations
64.29% 9 Buy Ratings
Companies Covered
9 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy64.3%9 ratings
Hold35.7%5 ratings
Sell0.0%0 ratings

Out of 14 total stock ratings issued by Dennis Ding at Jefferies Financial Group, the majority (64.3%) have been Buy recommendations, followed by 35.7% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
9 companies

Dennis Ding, an analyst at Jefferies Financial Group, currently covers 9 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
8 companies
88.9%
Manufacturing
1 company
11.1%

Dennis Ding of Jefferies Financial Group specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
55.6%
MED - DRUGS
2 companies
22.2%
MED - GENERIC DRG
1 company
11.1%
SURGICAL, MEDICAL, AND DENTAL INSTRUMENTS AND SUPPLIES
1 company
11.1%

Dennis Ding's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
4/21/2026Reiterated Rating$22.92$22.00Hold
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
3/19/2026Initiated Coverage$14.60$40.00Buy
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
3/13/2026Reiterated Rating$26.81$30.00Hold
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3/3/2026Reiterated Rating$89.56$125.00Buy
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3/3/2026Reiterated Rating$28.15Buy
Spyglass Pharma, Inc. stock logo
SGP
Spyglass Pharma
3/3/2026Initiated Coverage$26.73$62.00Buy
Spyglass Pharma, Inc. stock logo
SGP
Spyglass Pharma
3/3/2026Initiated Coverage$26.75$62.00Buy
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2/9/2026Reiterated Rating$25.86$30.00Buy
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
1/22/2026Reiterated Rating$14.35$14.50Hold
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
9/18/2025Boost Price Target$15.17$20.00Buy
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
9/3/2025Boost Price Target$28.86$26.00Hold
Indivior PLC stock logo
INDV
Indivior
7/22/2025Initiated Coverage$15.60$20.00Buy
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
6/10/2025Initiated Coverage$16.03$15.00Hold
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
1/22/2025Upgrade$38.76$55.00Buy